- Home
- EDF vs MRSN Comparison
EDF vs MRSN Comparison
Compare EDF & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDF | MRSN |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.9M | 138.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | EDF | MRSN |
|---|---|---|
| Price | $4.88 | $28.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.38 |
| AVG Volume (30 Days) | 160.6K | ★ 238.9K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,180,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $5.21 |
| 52 Week High | $5.50 | $70.13 |
Technical Indicators
Market Signals| Indicator | EDF | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 84.04 |
| Support Level | $4.88 | $27.31 |
| Resistance Level | $4.95 | $28.63 |
| Average True Range (ATR) | 0.05 | 0.54 |
| MACD | -0.00 | -0.47 |
| Stochastic Oscillator | 40.00 | 64.86 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.